Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 70.48 USD 0.14% Market Closed
Market Cap: 41.6B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Wall Street
Price Targets

EW Price Targets Summary
Edwards Lifesciences Corp

Wall Street analysts forecast EW stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EW is 76.62 USD with a low forecast of 63.63 USD and a high forecast of 94.5 USD.

Lowest
Price Target
63.63 USD
10% Downside
Average
Price Target
76.62 USD
9% Upside
Highest
Price Target
94.5 USD
34% Upside

EW Last Price Targets
Edwards Lifesciences Corp

The latest public price target was made on Oct 30, 2024 by David Roman from Goldman Sachs , who expects EW stock to rise by 14% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Roman
Goldman Sachs
80 USD
Upside 14%
3 weeks ago
Oct 30, 2024
Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
StreetInsider
Travis Steed
Bank of America Securities
75 USD
Upside 6%
3 weeks ago
Oct 30, 2024
BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)
StreetInsider
Joanne Wuensch
Citigroup
81 USD
Upside 15%
3 weeks ago
Oct 28, 2024
Edwards Lifesciences TAVR data better than expected, says Citi
TheFly
David Rescott
Robert W. Baird
73 USD
Upside 4%
1 month ago
Oct 15, 2024
Edwards Lifesciences (EW) PT Raised to $73 at Baird
StreetInsider
Patrick Wood
Morgan Stanley
70 USD
Downside 1%
1 month ago
Oct 11, 2024
Edwards Lifesciences resumed with an Equal Weight at Morgan Stanley
TheFly
William Plovanic
Canaccord Genuity
66 USD
Downside 6%
1 month ago
Oct 7, 2024
Edwards Lifesciences price target lowered to $66 from $77 at Canaccord
TheFly
Matthew Taylor
Jefferies
70 USD
Downside 1%
2 months ago
Sep 18, 2024
Jefferies Downgrades Edwards Lifesciences (EW) to Hold
StreetInsider
Richard Newitter
Truist Financial
71 USD
Upside 1%
2 months ago
Sep 13, 2024
Edwards Lifesciences (EW) PT Lowered to $71 at Truist Securities
StreetInsider
Larry Biegelsen
Wells Fargo
80 USD
Upside 14%
2 months ago
Sep 9, 2024
Edwards Lifesciences price target lowered to $80 from $90 at Wells Fargo
TheFly
Matt Miksic
Barclays
80 USD
Upside 14%
2 months ago
Sep 9, 2024
Edwards Lifesciences price target lowered to $80 from $90 at Barclays
TheFly
Narumi Nakagiri
Daiwa
72 USD
Upside 2%
3 months ago
Jul 31, 2024
Daiwa Securities Upgrades Edwards Lifesciences (EW) to Outperform (2)
StreetInsider
Joanna Wuensch
Citigroup
83 USD
Upside 18%
3 months ago
Jul 30, 2024
Edwards Lifesciences (EW) PT Lowered to $83 at Citi
StreetInsider
Pito Chickering
Deutsche Bank
85 USD
Upside 21%
3 months ago
Jul 25, 2024
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Benzinga
Rick Wise
Stifel Nicolaus
70 USD
Downside 1%
3 months ago
Jul 25, 2024
Edwards Lifesciences price target lowered to $70 from $85 at Stifel
TheFly
Suraj Kalia
Oppenheimer
90 USD
Upside 28%
3 months ago
Jul 25, 2024
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Benzinga
Shagun Singh
RBC Capital
85 USD
Upside 21%
3 months ago
Jul 25, 2024
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Benzinga
Robbie Marcus
J.P. Morgan
72 USD
Upside 2%
3 months ago
Jul 25, 2024
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Benzinga
Adam Maeder
Piper Sandler
73 USD
Upside 4%
3 months ago
Jul 25, 2024
Edwards Lifesciences price target lowered to $73 from $88 at Piper Sandler
TheFly
Richard Newitter
Truist Financial
110 USD
Upside 56%
4 months ago
Jul 16, 2024
Edwards Lifesciences price target raised to $110 from $105 at Truist
TheFly
David Roman
Goldman Sachs
107 USD
Upside 52%
5 months ago
May 30, 2024
Goldman Sachs Starts Edwards Lifesciences (EW) at Buy
StreetInsider
Pito Chickering
Deutsche Bank
103 USD
Upside 46%
6 months ago
May 14, 2024
Edwards Lifesciences (EW) PT Raised to $103 at Deutsche Bank, 'Evoque will bring EW back to its golden years'
StreetInsider
Shagun Singh
RBC Capital
101 USD
Upside 43%
7 months ago
Apr 15, 2024
Edwards Lifesciences price target raised to $101 from $95 at RBC Capital
TheFly
Anthony Petrone
Mizuho Securities
105 USD
Upside 49%
7 months ago
Apr 11, 2024
Edwards Lifesciences price target raised to $105 from $95 at Mizuho
TheFly
Suraj Kalia
Oppenheimer
100 USD
Upside 42%
8 months ago
Mar 18, 2024
Edwards Lifesciences (EW) PT Raised to $100 at Oppenheimer
StreetInsider
Unknown Analyst
Canaccord Genuity
76 USD
Upside 8%
1 year ago
Feb 1, 2023
Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $76
Benzinga
Unknown Analyst
Truist Financial
86 USD
Upside 22%
1 year ago
Feb 1, 2023
Truist Securities Maintains Buy on Edwards Lifesciences, Raises Price Target to $86
Benzinga
Show More Price Targets
Show Less Price Targets
David Roman
Goldman Sachs
Price Target 80 USD
Upside/Downside 14%
View Source
Travis Steed
Bank of America Securities
Price Target 75 USD
Upside/Downside 6%
View Source
Joanne Wuensch
Citigroup
Price Target 81 USD
Upside/Downside 15%
View Source
David Rescott
Robert W. Baird
Price Target 73 USD
Upside/Downside 4%
View Source
Patrick Wood
Morgan Stanley
Price Target 70 USD
Upside/Downside 1%
View Source
William Plovanic
Canaccord Genuity
Price Target 66 USD
Upside/Downside 6%
View Source
Matthew Taylor
Jefferies
Price Target 70 USD
Upside/Downside 1%
View Source
Richard Newitter
Truist Financial
Price Target 71 USD
Upside/Downside 1%
View Source
Larry Biegelsen
Wells Fargo
Price Target 80 USD
Upside/Downside 14%
View Source
Matt Miksic
Barclays
Price Target 80 USD
Upside/Downside 14%
View Source
Narumi Nakagiri
Daiwa
Price Target 72 USD
Upside/Downside 2%
View Source
Joanna Wuensch
Citigroup
Price Target 83 USD
Upside/Downside 18%
View Source
Pito Chickering
Deutsche Bank
Price Target 85 USD
Upside/Downside 21%
View Source
Rick Wise
Stifel Nicolaus
Price Target 70 USD
Upside/Downside 1%
View Source
Suraj Kalia
Oppenheimer
Price Target 90 USD
Upside/Downside 28%
View Source
Shagun Singh
RBC Capital
Price Target 85 USD
Upside/Downside 21%
View Source
Robbie Marcus
J.P. Morgan
Price Target 72 USD
Upside/Downside 2%
View Source
Adam Maeder
Piper Sandler
Price Target 73 USD
Upside/Downside 4%
View Source
Richard Newitter
Truist Financial
Price Target 110 USD
Upside/Downside 56%
View Source
David Roman
Goldman Sachs
Price Target 107 USD
Upside/Downside 52%
View Source
Pito Chickering
Deutsche Bank
Price Target 103 USD
Upside/Downside 46%
View Source
Shagun Singh
RBC Capital
Price Target 101 USD
Upside/Downside 43%
View Source
Anthony Petrone
Mizuho Securities
Price Target 105 USD
Upside/Downside 49%
View Source
Suraj Kalia
Oppenheimer
Price Target 100 USD
Upside/Downside 42%
View Source
Unknown Analyst
Canaccord Genuity
Price Target 76 USD
Upside/Downside 8%
View Source
Unknown Analyst
Truist Financial
Price Target 86 USD
Upside/Downside 22%
View Source
Show More Price Targets
Show Less Price Targets
Edwards Lifesciences Corp Competitors:
Price Targets
SEDANA
Sedana Medical AB (publ)
105% Upside
688301
iRay Technology Co Ltd
76% Upside
LIVN
LivaNova PLC
40% Upside
7817
Paramount Bed Holdings Co Ltd
19% Upside
PODD
Insulet Corp
7% Upside
STIL
Stille AB
30% Upside
2235
MicroTech Medical Hangzhou Co Ltd
4% Upside
7733
Olympus Corp
28% Upside

Revenue
Forecast

Revenue Estimate
Edwards Lifesciences Corp

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's revenue is 12%. The projected CAGR for the next 3 years is 4%.

12%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Edwards Lifesciences Corp

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's operating income is 13%. The projected CAGR for the next 3 years is 6%.

13%
Past Growth
6%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Edwards Lifesciences Corp

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's net income is 14%. The projected CAGR for the next 3 years is 7%.

14%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-8%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EW's stock price target?
Price Target
76.62 USD

According to Wall Street analysts, the average 1-year price target for EW is 76.62 USD with a low forecast of 63.63 USD and a high forecast of 94.5 USD.

What is Edwards Lifesciences Corp's Revenue forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's revenue is 12%. The projected CAGR for the next 3 years is 4%.

What is Edwards Lifesciences Corp's Operating Income forecast?
Projected CAGR
6%

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's operating income is 13%. The projected CAGR for the next 3 years is 6%.

What is Edwards Lifesciences Corp's Net Income forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Edwards Lifesciences Corp's net income is 14%. The projected CAGR for the next 3 years is 7%.

Back to Top